B
Bing Xiao
Publications - 6
Citations - 2822
Bing Xiao is an academic researcher. The author has contributed to research in topics: Hazard ratio & Framingham Risk Score. The author has an hindex of 4, co-authored 5 publications receiving 1956 citations.
Papers
More filters
Journal ArticleDOI
Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes.
Lihua Zhu,Zhi-Gang She,Xu Cheng,Juan Juan Qin,Xiao Jing Zhang,Jingjing Cai,Fang Lei,Haitao Wang,Jing Xie,Wenxin Wang,Haomiao Li,Peng Zhang,Xiaohui Song,Xi Chen,Xiang Mei,Chaozheng Zhang,Liangjie Bai,Da Xiang,Ming Ming Chen,Yanqiong Liu,Youqin Yan,Mingyu Liu,Weiming Mao,Jinjing Zou,Liming Liu,Guohua Chen,Pengcheng Luo,Bing Xiao,Changjiang Zhang,Zixiong Zhang,Zhigang Lu,Junhai Wang,Haofeng Lu,Xigang Xia,Daihong Wang,Xiaofeng Liao,Gang Peng,Ping Ye,Jun Yang,Yufeng Yuan,Xiaodong Huang,Jiao Guo,Bing Hong Zhang,Hongliang Li +43 more
TL;DR: Clinical evidence correlating improved glycemic control with better outcomes in patients with COVID-19 and pre-existing T2D is provided, associated with markedly lower mortality compared to individuals with poorly controlled BG during hospitalization.
Journal ArticleDOI
Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19.
Peng Zhang,Lihua Zhu,Jingjing Cai,Fang Lei,Juan-Juan Qin,Jing Xie,Ye-Mao Liu,Yan-Ci Zhao,Xuewei Huang,Lijin Lin,Meng Xia,Ming-Ming Chen,Xu Cheng,Xiao Zhang,Deliang Guo,Yuanyuan Peng,Yan-Xiao Ji,Jing Chen,Zhi-Gang She,Yibin Wang,Qingbo Xu,Renfu Tan,Haitao Wang,Jun Lin,Pengcheng Luo,Shouzhi Fu,Hongbin Cai,Ping Ye,Bing Xiao,Weiming Mao,Liming Liu,Youqin Yan,Mingyu Liu,Manhua Chen,Xiao-Jing Zhang,Xinghuan Wang,Rhian M. Touyz,Jiahong Xia,Bing-Hong Zhang,Xiaodong Huang,Yufeng Yuan,Rohit Loomba,Peter P. Liu,Hongliang Li +43 more
TL;DR: Among hospitalized patients with COVID-19 and coexisting hypertension, inpatient use of ACEI/ARB was associated with lower risk of all-cause mortality compared with ACEi/ARB nonusers, and it is unlikely that in-hospital use ofACEI/ARB wasassociated with an increased mortality risk.
Journal ArticleDOI
In-Hospital Use of Statins Is Associated with a Reduced Risk of Mortality among Individuals with COVID-19.
Xiao Jing Zhang,Juan Juan Qin,Xu Cheng,Li-Jun Shen,Yan Ci Zhao,Yufeng Yuan,Fang Lei,Ming Ming Chen,Huilin Yang,Liangjie Bai,Xiaohui Song,Lijin Lin,Meng Xia,Feng Zhou,Jianghua Zhou,Zhi-Gang She,Lihua Zhu,Xin-Liang Ma,Qingbo Xu,Ping Ye,Guohua Chen,Liming Liu,Weiming Mao,Youqin Yan,Bing Xiao,Zhigang Lu,Gang Peng,Mingyu Liu,Jun Yang,Luyu Yang,Changjiang Zhang,Haofeng Lu,Xigang Xia,Daihong Wang,Xiaofeng Liao,Xiang Wei,Bing Hong Zhang,Xin Zhang,Juan Yang,Guang Nian Zhao,Peng Zhang,Peter P. Liu,Rohit Loomba,Yan Xiao Ji,Jiahong Xia,Yibin Wang,Jingjing Cai,Jiao Guo,Hongliang Li +48 more
TL;DR: A retrospective study on 13,981 patients with COVID-19 in Hubei Province, China found that the risk for 28-day all-cause mortality was 5.2% and 9.4% in the matched statin and non-statin groups, respectively, with a hazard ratio 0.58, implying the potential benefits of statin therapy in hospitalized subjects with CO VID-19.
Journal ArticleDOI
Longitudinal Association Between Markers of Liver Injury and Mortality in COVID-19 in China.
Fang Lei,Ye Mao Liu,Feng Zhou,Juan Juan Qin,Peng Zhang,Lihua Zhu,Xiao Jing Zhang,Jingjing Cai,Lijin Lin,Shan Ouyang,Xiaoming Wang,Chengzhang Yang,Xu Cheng,Weifang Liu,Haomiao Li,Jing Xie,Bin Wu,Huiming Luo,Fei Xiao,Jing Chen,Liang Tao,Gang Cheng,Zhi-Gang She,Jianghua Zhou,Haitao Wang,Jun Lin,Pengcheng Luo,Shouzhi Fu,Jihui Zhou,Ping Ye,Bing Xiao,Weiming Mao,Liming Liu,Youqin Yan,Ling Liu,Guohua Chen,Hongliang Li,Xiaodong Huang,Bing Hong Zhang,Yufeng Yuan +39 more
TL;DR: To reveal the hepatic injury related to this disease and its clinical significance, a multicenter retrospective cohort study that included 5,771 adult patients with COVID‐19 pneumonia in Hubei Province was conducted.
Journal ArticleDOI
A risk score based on baseline risk factors for predicting mortality in COVID-19 patients.
Ze Chen,Jing Chen,Jing Chen,Jianghua Zhou,Fang Lei,Feng Zhou,Juan Juan Qin,Xiao Jing Zhang,Lihua Zhu,Ye Mao Liu,Haitao Wang,Ming Ming Chen,Yan Ci Zhao,Jing Xie,Li-Jun Shen,Xiaohui Song,Xingyuan Zhang,Chengzhang Yang,Weifang Liu,Xiao Zhang,Deliang Guo,Youqin Yan,Mingyu Liu,Weiming Mao,Liming Liu,Ping Ye,Bing Xiao,Pengcheng Luo,Zixiong Zhang,Zhigang Lu,Junhai Wang,Haofeng Lu,Xigang Xia,Daihong Wang,Xiaofeng Liao,Gang Peng,Liang Liang,Jun Yang,Guohua Chen,Elena Azzolini,Alessio Aghemo,Michele Ciccarelli,Gianluigi Condorelli,Giulio G. Stefanini,Xiang Wei,Bing Hong Zhang,Xiaodong Huang,Jiahong Xia,Yufeng Yuan,Zhi-Gang She,Jiao Guo,Yibin Wang,Peng Zhang,Hongliang Li +53 more
TL;DR: In this paper, the authors developed a sensitive and clinically applicable risk assessment tool identifying coronavirus disease 2019 (COVID-19) patients with a high risk of mortality at hospital admission.